Expanded NRDL Coverage + CIDL Inclusion in China

Summary by AI BETAClose X

HUTCHMED announced that ELUNATE®, ORPATHYS®, and SULANDA® will continue to be included on China's National Reimbursement Drug List effective January 1, 2026, following contract renewal with the China National Healthcare Security Administration. Additionally, TAZVERIK® will be added to the first National Commercial Health Insurance Innovative Drug List. ELUNATE® is indicated for advanced endometrial cancer and metastatic colorectal cancer, ORPATHYS® for non-small cell lung cancer with MET exon 14 skipping alteration, SULANDA® for neuroendocrine tumors, and TAZVERIK® for relapsed or refractory follicular lymphoma with EZH2 mutation. This expanded coverage and inclusion in the new commercial insurance list are expected to enhance patient access to these oncology treatments.

Disclaimer*

UK 100

Latest directors dealings